Regulus therapeutics investor alert by the former attorney general of louisiana: kahn swick & foti, llc investigates adequacy of price and process in proposed sale of regulus therapeutics inc. - rgls

New york city & new orleans--(business wire)--former attorney general of louisiana charles c. foti, jr., esq. and the law firm of kahn swick & foti, llc (“ksf”) are investigating the proposed sale of regulus therapeutics inc. (nasdaqcm: rgls) to novartis ag. under the terms of the proposed transaction, shareholders of regulus will receive $7.00 per share in cash and a contingent value right providing for payment of $7.00 per share, contingent upon the achievement of a milestone with respect.
GM Ratings Summary
GM Quant Ranking